Answers are grounded in this paper and cite their sources.
Review highlights advances and challenges in molecular and point-of-care diagnostics for invasive fungal infections, suggesting a need for standardized and accessible testing.
Invasive fungal infection (IFI) is responsible for millions of deaths globally each year. Prompt diagnosis of IFI is critical, with delay associated with increased mortality. Traditional, culture-based diagnostics are relatively slow and insensitive. Novel molecular techniques, biomarkers and point-of-care tests hope to overcome these limitations. However, these newer methods come with issues of cost, accessibility, and standardisation. This review briefly lays out the current diagnostic landscape, highlights important changes to standards of care, then explores new developments and the future of fungal laboratory diagnosis.
No takes yet. Share an insight, caveat, or question.
Southern-Thomas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: